Apoquel (Oclacitinib) Tablets for Dogs, 16mg

Apoquel Tablets control itching (pruritis) associated with allergic dermatitis and control atopic dermatitis in dogs at least 12 months of age. It goes right to the source to help stop itching and relieve associated inflammation in affected canines providing relief in as little as 4 hours. Apoquel is given twice daily for up to 14 days, and then given once daily for maintenance therapy. You can use for both short-term or long-term therapy in your dog and discontinue use without tapering. Since Apoquel is neither a steroid nor an antihistamine, your dog will avoid many of the unpleasant side effects that are often associated with these medications.

#1 Prescribed Oral Medicine for Allergic Itch [1]: Apoquel is a revolutionary oral medicine for dogs with allergic itch. Apoquel can be used short-term or for long-term maintenance therapy [2,3] in dogs 12 months of age and older.
Stops allergic itch at the source [4]: Apoquel is not a steroid, antihistamine, or cyclosporine. Apoquel is in a different category of medications. Unlike other medicines, Apoquel blocks allergic itch at the source. So, it works at the underlying cause of itch to provide relief fast.
Fast-Acting Allergy Itch Relief: If your dog is scratching, licking, or chewing like crazy, you want to provide fast, effective relief. Apoquel Tablets start relieving allergic itch within 4 hours [5] and control it within 24 hours [2]. Apoquel has been prescribed to over 14 million dogs and counting [6].
Can be used with many other medications [3]
Available in Three Strengths: Follow your veterinarian’s instructions for dosing as prescribed. You can administer to your dog orally once a day with or without food. Apoquel is now available in a pork-liver flavored chewable.

IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines. See full Prescribing Information for Apoquel Tablet at ApoquelPI.com and full Prescribing Information for Apoquel Chewable at ApoquelChewablePI.com.
 

INDICATIONS: Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
 *Vets, n=250; pet owners, n=491.
 1. Data on file, ZMR: Kynetec PetTrak – Pets Since Launch, December 2022, Zoetis Inc.; 2. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi: 10.1111/vde.12047; 3. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179, e35. doi:10.1111/vde.12194; 4. Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL)is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Therapy. 2014;37(4)317-24. doi:10.1111/jvp.12101; 5. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518,e86. doi:10.1111/vde.12166; 6. ZMR: GAH-284 Pets Since Launch September 2023 Data (TI-10330); 7. Data on file, APOQUEL/CYTOPOINT Pet Owner Tracker Wave 11, 2022, Zoetis Inc.; 8. Data on File, APOQUEL/CYTOPOINT Vet Tracker Wave 17, 2022, Zoetis Inc. TI-08426